Back to News
Market Impact: 0.2
HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
HC Wainwright & Co. initiated coverage of Monte Rosa Therapeutics (NASDAQGS: GLUE) with a Buy rating on October 1, 2026. GLUE closed at $11.93 on September 30 before the rating action, providing a positive analyst catalyst but with likely limited impact beyond the individual stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
GLUE0.45
More News
- Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
- Europe’s winter energy crunch may already be underway. Two U.S. stocks that may benefit
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Google unveils latest AI model, but Wall Street wants a breakout personal agent
- You think Nvidia's $235 billion buyback is big. Just wait and see what Micron might do
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework